Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CARM Carisma Therapeutics	$0.24 +2.9%	$0.37	$0.14 ▼ $1.27	$9.86M	1.79	5.76 million shs	819,260 shs
EVGN Evogene	$1.31 +2.4%	$1.33	$0.95 ▼ $3.93	$7.01M	1.59	869,972 shs	16,853 shs
IPSC Century Therapeutics	$0.54 +0.0%	$0.57	$0.34 ▼ $2.05	$46.75M	1.78	727,147 shs	1.03 million shs
STTK Shattuck Labs	$0.96 +7.3%	$0.86	$0.69 ▼ $3.95	$45.98M	1.63	846,772 shs	489,082 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CARM Carisma Therapeutics	-4.06%	-19.59%	-40.51%	+24.00%	-81.65%
EVGN Evogene	+4.51%	-6.25%	-1.93%	+8.97%	-67.96%
IPSC Century Therapeutics	-0.72%	-1.62%	-5.94%	-3.17%	-69.77%
STTK Shattuck Labs	-11.42%	+3.99%	+11.48%	-17.16%	-73.92%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CARM Carisma Therapeutics	3.0433 of 5 stars	3.4	5.0	2.7	0.8	0.6
EVGN Evogene	2.7125 of 5 stars	3.8	3.0	3.1	0.0	0.6
IPSC Century Therapeutics	3.0127 of 5 stars	3.5	4.0	2.3	1.7	0.6
STTK Shattuck Labs	3.5172 of 5 stars	3.4	5.0	2.5	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CARM Carisma Therapeutics	2.71	Moderate Buy	$1.93	705.44% Upside
EVGN Evogene	3.50	Strong Buy	$3.50	171.32% Upside
IPSC Century Therapeutics	3.00	Buy	$3.75	579.35% Upside
STTK Shattuck Labs	2.83	Moderate Buy	$7.00	647.07% Upside

Current Analyst Ratings Breakdown

Latest CARM, EVGN, IPSC, and STTK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2025	STTK Shattuck Labs	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$4.00 ➝ $2.00
8/14/2025	STTK Shattuck Labs	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
8/11/2025	EVGN Evogene	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/8/2025	CARM Carisma Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$1.00
7/15/2025	CARM Carisma Therapeutics	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/22/2025	EVGN Evogene	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$5.00 ➝ $3.50

(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CARM Carisma Therapeutics	$19.63M	0.51	N/A	N/A	($1.10) per share	-0.22
EVGN Evogene	$8.51M	0.81	N/A	N/A	$2.31 per share	0.56
IPSC Century Therapeutics	$6.59M	7.24	N/A	N/A	$2.43 per share	0.23
STTK Shattuck Labs	$5.72M	7.85	N/A	N/A	$1.19 per share	0.79

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CARM Carisma Therapeutics	-$60.48M	-$1.56	N/A	N/A	N/A	-254.28%	N/A	-192.17%	11/5/2025 (Estimated)
EVGN Evogene	-$16.49M	-$2.25	N/A	∞	N/A	-211.61%	-109.96%	-38.47%	N/A
IPSC Century Therapeutics	-$126.57M	-$0.29	N/A	N/A	N/A	-19.10%	-11.53%	-6.94%	11/4/2025 (Estimated)
STTK Shattuck Labs	-$75.41M	-$1.21	N/A	N/A	N/A	N/A	-81.80%	-71.46%	N/A

Latest CARM, EVGN, IPSC, and STTK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/14/2025	Q2 2025	IPSC Century Therapeutics	-$0.38	-$0.38	N/A	-$0.38	$0.03 million	N/A
8/14/2025	Q2 2025	STTK Shattuck Labs	-$0.25	-$0.24	+$0.01	-$0.24	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CARM Carisma Therapeutics	N/A	N/A	N/A	N/A	N/A
EVGN Evogene	N/A	N/A	N/A	N/A	N/A
IPSC Century Therapeutics	N/A	N/A	N/A	N/A	N/A
STTK Shattuck Labs	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CARM Carisma Therapeutics	N/A	0.48	0.48
EVGN Evogene	N/A	1.89	0.92
IPSC Century Therapeutics	N/A	10.72	11.70
STTK Shattuck Labs	N/A	10.25	9.08

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CARM Carisma Therapeutics	44.27%
EVGN Evogene	10.40%
IPSC Century Therapeutics	50.20%
STTK Shattuck Labs	58.74%

Insider Ownership

Company	Insider Ownership
CARM Carisma Therapeutics	6.90%
EVGN Evogene	7.40%
IPSC Century Therapeutics	5.00%
STTK Shattuck Labs	12.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CARM Carisma Therapeutics	20	41.79 million	38.91 million	No Data
EVGN Evogene	140	5.37 million	4.97 million	Optionable
IPSC Century Therapeutics	170	86.39 million	82.07 million	Optionable
STTK Shattuck Labs	100	47.90 million	42.16 million	Optionable

CARM, EVGN, IPSC, and STTK Headlines

Recent News About These Companies

Shattuck Labs, Inc.: Shattuck Labs Announces IND for SL-325 Is in Effect for the Treatment of Inflammatory Bowel Disease

August 22 at 10:45 AM | finanznachrichten.de

Shattuck Labs Reports Q2 2025 Financial Results

August 22 at 10:45 AM | msn.com

Shattuck Labs says IND for SL-325 for treatment of IBD in effect

August 22 at 10:45 AM | msn.com

Shattuck Labs Announces IND for SL-325 Is in Effect for the Treatment of Inflammatory Bowel Disease

August 21 at 10:17 AM | globenewswire.com

Shattuck Labs raises up to $103M to fund therapeutic antibody development

August 19 at 7:07 PM | ncbiotech.orgN

Shattuck Labs, Inc. (NASDAQ:STTK) Given Average Recommendation of "Moderate Buy" by Brokerages

August 19 at 2:09 AM | americanbankingnews.com

Leerink Partnrs Estimates Shattuck Labs Q1 Earnings

August 18, 2025 | americanbankingnews.com

Shattuck Labs' (STTK) "Hold" Rating Reiterated at Needham & Company LLC

August 17, 2025 | americanbankingnews.com

Shattuck Labs (NASDAQ:STTK) Price Target Lowered to $2.00 at Leerink Partners

August 16, 2025 | americanbankingnews.com

Shattuck Labs price target lowered to $2 from $4 at Leerink

August 14, 2025 | msn.com

Shattuck Labs Submits IND Application for SL-325; Phase 1 Trial in Healthy Volunteers Expected to Begin Q3 2025

August 14, 2025 | quiverquant.comQ

Shattuck Labs Reports Second Quarter 2025 Financial Results and Recent Business Highlights

August 14, 2025 | globenewswire.com

Shattuck Labs expects $103 million from private placing

August 6, 2025 | thepharmaletter.comT

Shattuck Labs Announces Oversubscribed Private Placement of Up to Approximately $103 Million

August 5, 2025 | globenewswire.com

Shattuck Labs Elects Directors, Approves Auditor at Meeting

July 15, 2025 | tipranks.com

Shattuck Labs Announces Participation in Upcoming Leerink Partners Therapeutics Forum: I&I and Metabolism

July 2, 2025 | globenewswire.com

Shattuck Labs, Inc. (STTK) - Yahoo Finance

June 28, 2025 | finance.yahoo.com

Here's Why We're Watching Shattuck Labs' (NASDAQ:STTK) Cash Burn Situation

June 13, 2025 | finance.yahoo.com

Shattuck Labs Advances SL-325 Program Amid Financial Progress

May 5, 2025 | tipranks.com

Shattuck Labs Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 1, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CARM, EVGN, IPSC, and STTK Company Descriptions

Carisma Therapeutics NASDAQ:CARM

$0.24 +0.01 (+2.88%)

Closing price 04:00 PM Eastern

Extended Trading

$0.24 0.00 (0.00%)

As of 06:41 PM Eastern

Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.

Evogene NASDAQ:EVGN

$1.30 +0.03 (+2.35%)

Closing price 03:50 PM Eastern

Extended Trading

$1.31 +0.01 (+0.38%)

As of 06:07 PM Eastern

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.

Century Therapeutics NASDAQ:IPSC

$0.54 +0.00 (+0.02%)

Closing price 04:00 PM Eastern

Extended Trading

$0.55 +0.00 (+0.70%)

As of 06:33 PM Eastern

Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

Shattuck Labs NASDAQ:STTK

$0.96 +0.07 (+7.30%)

Closing price 04:00 PM Eastern

Extended Trading

$0.94 -0.02 (-2.08%)

As of 06:17 PM Eastern

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time